FBL: A Protein with Potential for Treating A Wide Range of Diseases

Target Name: FBL

NCBI ID: G2091

Content of Review Report on FBL Target / Biomarker

FBL

FBL: A Protein with Potential for Treating A Wide Range of Diseases

FBL (short for Fusoblastinin-Bla-LUNAT1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a key regulator of cell survival and has been implicated in a number of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

One of the unique features of FBL is its ability to interact with other proteins and molecules, including the nuclear factor of activating T cells (NFAT). NFAT is a transcription factor that plays a critical role in the development and maintenance of tissues, including the brain. It is expressed in a variety of tissues and has been implicated in a number of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

FBL has been shown to play a role in regulating the activity of NFAT, and in modulating the expression of genes that are involved in cell survival and differentiation. This suggests that FBL may be a potential drug target or biomarker for a variety of diseases.

One of the potential benefits of targeting FBL is its potential to treat a wide range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. For example, FBL has been shown to play a role in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development of cancer, including breast and ovarian cancer.

In addition to its potential therapeutic applications, FBL is also a valuable research tool for the study of gene function and the development of new therapeutic approaches. By studying the mechanisms of FBL's activity, researchers can gain insights into the regulation of cell survival and differentiation, and use this knowledge to develop new treatments for a variety of diseases.

Overall, FBL is a protein that has significant potential as a drug target or biomarker for a wide range of diseases. Further research is needed to fully understand its mechanisms of action and its potential therapeutic applications.

Protein Name: Fibrillarin

Functions: S-adenosyl-L-methionine-dependent methyltransferase that has the ability to methylate both RNAs and proteins (PubMed:24352239, PubMed:30540930, PubMed:32017898). Involved in pre-rRNA processing by catalyzing the site-specific 2'-hydroxyl methylation of ribose moieties in pre-ribosomal RNA (PubMed:30540930). Site specificity is provided by a guide RNA that base pairs with the substrate (By similarity). Methylation occurs at a characteristic distance from the sequence involved in base pairing with the guide RNA (By similarity). Probably catalyzes 2'-O-methylation of U6 snRNAs in box C/D RNP complexes (PubMed:32017898). U6 snRNA 2'-O-methylation is required for mRNA splicing fidelity (PubMed:32017898). Also acts as a protein methyltransferase by mediating methylation of 'Gln-105' of histone H2A (H2AQ104me), a modification that impairs binding of the FACT complex and is specifically present at 35S ribosomal DNA locus (PubMed:24352239, PubMed:30540930). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797)

The "FBL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets